— Dr. Smith is a 20-year pharmaceutical industry veteran with extensive experience in central nervous system (“CNS”) clinical development —
VANCOUVER, British Columbia, November 23, 2022 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds”, “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on in developing new drugs for the targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that Mark A. Smith MD, Ph.D. will join the company as Chief Medical Officer, effective December 1, 2022. The company also announces that Dr. Revati Shreeniwas with Bright Minds as Medical Director has been terminated.
“I am thrilled to welcome Dr. Smith to the Bright Minds team. An executive experienced in CNS drug development, Dr. Smith has directed over 50 clinical trials at all stages of development. The extensive experience of Dr. Smith in Psychiatry Will Strengthen Clinical Implementation of Our Next Generation of 5-HTtwoONE agonists. His depth and breadth of knowledge in neuropsychiatry, development, translational neuroscience, and clinical trial design will be a great asset as we continue to advance our pipeline of new compounds through clinical trials,” said Ian McDonald, CEO and co-founder of Bright Minds Biosciences.
“It is an exciting time to join Bright Minds with Phase I testing of its flagship program, BMB-101, currently underway. Proposed to treat Dravet syndrome, an epileptic syndrome that begins in infancy or early childhood, BMB-101 is a promising drug candidate with the potential to change lives. My experience is uniquely suited to the opportunity and I look forward to seeing the BMB-101 and the remainder of the pipeline through its development stages,” said Dr. Smith.
Prior to joining Bright Minds, Dr. Smith was medical director at VistaGen Therapeutics, where he led the clinical development of drug candidates in the areas of major depression, social anxiety disorder, and depression in all stages of development. Previously, Dr. Smith served as clinical lead for neuropsychiatry at Teva Pharmaceuticals, where he was responsible for strategy and clinical development of neuropsychiatric drugs with a focus on schizophrenia, sleep disorders and agitation. He has also held a number of management positions, including as Executive Director of Clinical Development at AstraZeneca Pharmaceutical Company, where he led the development of several new chemical entities targeting treatment-resistant depression, anxiety and schizophrenia.
The Doctor. Smith was also Senior Director of Experimental Medicine Global Clinical Development and Innovation at Shire Pharmaceuticals and Senior Investigator and Principal Scientist CNS Disease Research at DuPont Pharmaceuticals. Prior to joining the pharmaceutical industry, he served as a senior scientist in the Division of Biological Psychiatry and a senior staff member in the Division of Clinical Neuroendocrinology at the US National Institute of Mental Health (NIMH).
Dr. Smith received his Bachelor’s and Master of Science degrees from Yale University, his Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California, San Diego, and completed his residency in the Department of Psychiatry at Duke University Medical Center. He currently serves on the Translational Neuropsychopharmacology Task Force at the National Institute of Mental Health.
About Brilliant Minds
Bright Minds is focused on developing new transformative treatments for neuropsychiatric disorders, epilepsy and pain. Bright Minds has a portfolio of state-of-the-art serotonin agonists designed to target neurocircuitry abnormalities responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD and pain. The company leverages its world-class scientific and drug development expertise to deliver the next generation of safe and effective medicines. Bright Minds’ drugs were designed to potentially retain the powerful therapeutic aspects of psychedelics and other serotonergic compounds, while minimizing side effects, thus creating drugs superior to first-generation compounds such as psilocybin.
AND: [email protected]
CEO and Director
E: [email protected]
T: 647 407 2515
This press release contains “forward-looking information” which may include, but is not limited to, statements regarding the intended date expectations that Dr. Smith becomes CMO, his job in relation to the company’s development pipeline and the proposed use of BMB-101 to treat Dravet Syndrome. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “believes” or variations (including negative variations) of such words and phrases, or represents that certain actions, events or results “may”, “could”, “could”, “could” or “will” be taken, will occur or be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information contained in this press release. Additional risk factors can also be found in the company’s public files on the company’s SEDAR profile at www.sedar.com. The forward-looking statements contained in this document are made as of the date of this press release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There is no guarantee that forward-looking statements will be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances, estimates or management’s opinions change, except as required by securities law. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.
Neither the Canadian Stock Exchange nor its Regulatory Services Provider accepts responsibility for the adequacy or accuracy of this notice.